RGN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow provides durable internal funding for R&D, modest capex (~3–4% of revenue), and M&A such as BioLife without relying solely on external financing. Strong cash buffers also support working capital through biotech cycle troughs, improving resilience.
Diversified High-growth FranchisesMultiple end-market growth engines reduce single-product cyclicality: high growth in Analytics and Chromatography, plus proteins and consumables recurring demand, create a balanced revenue mix. This structural diversification supports steadier organic growth and margin durability as biologics production expands.
Strategic Expansion Into Cell TherapyAcquiring BioLife meaningfully expands exposure to cell therapy and biopreservation platforms that serve commercial cell-based therapies. The deal is positioned to be accretive with near-term synergy targets, strengthening product portfolio and market position in a structurally growing segment.
Bears Say
Volatile Revenue & Low ReturnsHistorical volatility in revenue and margins and persistently low ROE indicate the company has not fully converted its asset base into consistent high returns. Structural variability in end-market demand and prior losses mean capital allocation must be disciplined to improve long-term capital efficiency.
M&A And Integration RiskWhile strategic, the BioLife acquisition requires regulatory approvals and successful integration to realize projected synergies. M&A execution risk can strain management bandwidth, incur unexpected costs, and delay accretion, making projected long-term benefits contingent on effective integration.
Customer Timing & China CompetitionRevenue, especially for capital equipment and ATF, is sensitive to customer facility readiness and program timing, creating lumpy receipts. Separately, intensifying local competition in China forces localization and OEM strategies that delay market capture and increase execution complexity over the medium term.
Repligen News
RGN FAQ
What was Repligen Corp’s price range in the past 12 months?
Currently, no data Available
What is Repligen Corp’s market cap?
Repligen Corp’s market cap is CHF7.47B.
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Nov 03, 2026 which is in 82 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Jul 28, 2026. The company reported CHF0.437 earnings per share for the quarter, beating the consensus estimate of CHF0.362 by CHF0.075.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is 0.37.
How many shares outstanding does Repligen Corp have?
Currently, no data Available
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of CHF0.437 in its last earnings report, beating expectations of CHF0.362. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Repligen Corp?
Currently, no hedge funds are holding shares in CH:RGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF139.47 (― Upside)
CHF139.47 (― Upside)
Blogger Sentiment
Bullish
CH:RGN Sentiment 75%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.67%
Trailing 12-Months
Company Description
Repligen Corp
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
RGN Company Deck
RGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: the company reported healthy top-line growth ($194M, +15% reported, +11% organic), notable margin expansion (gross margin +180 bps, operating margin +160 bps), strong franchise performances (Analytics +50%+, Chromatography >25%, Proteins mid-teens), solid cash position ($785M), and raised adjusted EPS guidance. Management launched a transformation office targeting at least 1 point of annualized margin benefit by end of 2027 and announced a strategic OEM partnership in China. Key headwinds are mostly timing and structural: divestiture of a loss-making Polymem reduced revenue (~$7M), ATF/gene therapy customer timing moderated near-term growth (expected to rebound in 2027), some Q1 margin benefits may normalize, and there is execution risk around customer readiness for capital equipment and competition in China. Overall, positives (growth, margins, guidance, strategic initiatives, cash) materially outweigh the manageable lowlights tied to timing, one-off costs, and a small divestiture impact.View all CH:RGN earnings summariesRGN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGN Stock 12 Month Forecast
Average Price Target
―AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―